SCHEMBL20029261

SCHEMBL20029261

Cc1noc(-c2ccccc2)c1NC(=O)C(=O)OCc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LPAR1 Q92633 5/20 0.54
LPAR3 Q9UBY5 3/20 0.54
KDM4E B2RXH2 2/20 0.52
MAPT P10636 2/20 0.52
KMT2A Q03164 2/20 0.46
LPAR2 Q9HBW0 2/20 0.45
FTO Q9C0B1 1/20 0.44
ALDH1A1 P00352 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
TSHR P16473 2/20 0.43
RAB9A P51151 2/20 0.43
NPSR1 Q6W5P4 1/20 0.42
HSD17B10 Q99714 1/20 0.42
ABCC3 O15438 1/20 0.42
ABCC4 O15439 1/20 0.42
ABCB11 O95342 1/20 0.42
CYP2C8 P10632 1/20 0.42
CYP2C9 P11712 1/20 0.42
ABCB4 P21439 1/20 0.42
ABCC2 Q92887 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4029141 0.88 LPAR1 (0.62) LPAR1LPAR3KDM4EMAPTLPAR2
SCHEMBL343051 0.81 LPAR1 (0.56) LPAR1LPAR3KDM4EMAPTLPAR2
SCHEMBL4035675 0.79 MAPT (0.67) LPAR1LPAR3KDM4EMAPTKMT2A
SCHEMBL4034023 0.76 LPAR1 (0.53) LPAR1LPAR3KDM4EMAPTKMT2A
SCHEMBL5529169 0.75 MAPT (0.62) LPAR1LPAR3KDM4EMAPTKMT2A
SCHEMBL4033885 0.75 LPAR1 (0.52) LPAR1LPAR3KDM4EMAPTKMT2A
SCHEMBL15897074 0.75 LPAR1 (0.48) LPAR1LPAR3KDM4EMAPTLPAR2
SCHEMBL343594 0.75 LPAR1 (0.69) LPAR1LPAR3KDM4EMAPTLPAR2
SCHEMBL4032711 0.74 LPAR1 (0.48) LPAR1LPAR3KDM4EMAPTLPAR2
SCHEMBL28398519 0.73 LPAR1 (0.49) LPAR1LPAR3KDM4EMAPTLPAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180093981-A1 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors GENZYME CORPORATION 2018-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180093981-A1 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors ASAH2, GBA1, GAA LPAR1 2360/4885LPAR3 3550/4885KDM4E 3499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.